Immunic's oral imu-856 demonstrated dose-dependent increase of glp-1 in celiac disease patients and corresponding effects in preclinical testing

– new data suggests that imu-856 could be a potential oral treatment option for weight management; program is phase 2 ready – – dose-dependent increase of endogenous glp-1 levels observed in post hoc analysis of patients from phase 1b clinical trial in celiac disease – – dose-dependent reduction of body weight gain and food consumption observed in preclinical study – – webcast to be held today, february 20 at 8:00 am et – new york , feb. 20, 2025 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that imu-856, an orally available and systemically acting small molecule modulator that targets sirt6 (sirtuin 6), demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (glp-1) levels in a post hoc analysis of patients from its phase 1b clinical trial in celiac disease. imu-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical in vivo testing.
IMUX Ratings Summary
IMUX Quant Ranking